Eliem Therapeutics (ELYM) just unveiled an update.
Eliem Therapeutics, Inc. has undergone significant changes with Dr. Valerie Morisset’s departure following the company’s shift in focus to autoimmune-driven inflammatory diseases. Dr. Morisset received a settlement agreement including salary and benefits. Meanwhile, Brett Kaplan has been promoted to principal financial officer after Andrew Levin stepped down as Executive Chairman, though Levin remains on the board. Kaplan’s appointment comes without additional compensation or changes to his existing agreements.
See more data about ELYM stock on TipRanks’ Stock Analysis page.
